Christopher Shea

Professor

University of Chicago
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Year:

2026

Year:

2026

Dr. Martin C. Mihm, Jr.'s innovative work on the dysplastic nevus achieved a milestone in his chapter in the World Health Organisation Classification of Skin Tumours (WHO‐C). WHO‐C presents a dichotomous classification (high‐grade versus low‐grade dysplastic nevi) and a quantitative metric to assess melanocytic nuclear enlargement. The Duke classification is a related approach that provides mostly quantitative histopathologic criteria for dysplastic nevi and gives due weight to architectural features as well as cytology. This paper proposes and illustrates updated criteria for scoring and grading melanocytic dysplasia, incorporating some of the definitions and categories of WHO‐C, while refining the quantitative and architectural elements of the Duke grading system to facilitate more detailed and precise assessment of dysplastic nevi.

Year:

2026

In 1973, Dr. Martin C. Mihm, Jr. presented the finding that congenital melanocytic nevi, when viewed at low magnification, resemble superficial and deep perivascular dermatitis, forming the so‐called “pseudoinflammatory” pattern. One year earlier, Dr. Richard A. Sagebiel had put forward the concept of “pseudovascular spaces” in melanocytic nevi. A retrospective look at these early studies confirms that alert observation at the microscope can lead to a deeper understanding of the fundamental biology underlying melanocytic tumors.

Year:

2026

In this Special Issue of the Journal of Cutaneous Pathology in memory of Dr. Martin C. Mihm, Jr, we highlight his many contributions over more than 50 years to the catalog of specific melanocytic tumor terminology. Dr. Mihm was an active participant in the International Melanoma Pathology Study Group (IMPSG). Discussions led to proposed recommendations for changes in the terminology of melanocytic tumors and their standardized diagnostic reporting. Histopathological reports of melanocytic tumors provide critical information that guides patient counseling and therapy. Importantly the pathology report must relay whether the melanocytic tumor is benign, intermediate, or malignant, and when appropriate, indicate diagnostic and/or prognostic uncertainty. Recent shifts in diagnostic terminology include the recommended use of the term “melanocytoma” to describe a morphologically and genetically defined subset of intermediate risk melanocytic tumors with higher (although still very low) risk of progression compared with benign nevi. Melanocytomas are distinguished from melanocytic tumors of uncertain malignant potential (MELTUMP) which are histopathologically indeterminate or uncertain tumors. In the setting of a broad lexicon for the reporting of melanocytic tumors, an assessment tool has been developed to map existing diverse terminologies into distinct hierarchical classes. The Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH‐Dx) V2.0 provides a four‐tiered classification scheme that is tiered by risk of tumor progression and recommended treatment. The purpose of this review is to report these shifts in diagnostic terminology, discussed and reviewed at the annual workshop of the IMPSG, in Edinburg, Scotland, in November 2022. This discussion included the use of the term melanocytoma, and the use of the MPATH‐Dx V2.0 classification and terminology for melanocytic tumors. Dr. Mihm was diligent in his attention to specific terminology, in his memory we aim to recommend terminology that improves communication in the care of those diagnosed with melanocytic tumors.

Year:

2026

Background: Early and precise diagnosis is vital to improving patient outcomes and reducing morbidity. In resource-limited settings, cancer diagnosis is often challenging due to shortages of expert pathologists. We assess the effectiveness of general-purpose pathology foundation models (FM) for the diagnosis and annotation of nonmelanoma skin cancer (NMSC) in resource-limited settings. Methods: We evaluated three pathology FMs (UNI, PRISM, and Prov-GigaPath) using deidentified NMSC histology images from the Bangladesh Vitamin E and Selenium Trial to predict cancer subtype based on zero-shot whole-slide embeddings. In addition, we evaluated tile aggregation methods and machine learning models for prediction. Lastly, we employed few-shot learning of PRISM tile embeddings to perform whole-slide annotation. Results: We found that the best model used PRISM’s aggregated tile embeddings to train a multilayer perceptron model to predict NMSC subtype [mean area under the receiver operating characteristic curve (AUROC) = 0.925, P < 0.001]. Within the other FMs, we found that using attention-based multi-instance learning to aggregate tile embeddings to train a multilayer perceptron model was optimal (UNI: mean AUROC = 0.913, P < 0.001; Prov-GigaPath: mean AUROC = 0.908, P < 0.001). We finally exemplify the utility of few-shot annotation in computation- and expertise-limited settings. Conclusions: Our study highlights the important role FMs may play in confronting public health challenges and exhibits a real-world potential for machine learning–aided cancer diagnosis. Impact: Pathology FMs offer a promising pathway to improve early and precise NMSC diagnosis, especially in resource-limited environments. These tools could also facilitate patient stratification and recruitment for prospective clinical trials aimed at improving NMSC management.

Year:

2025

INTRODUCTION: Janus kinase inhibitors (JAKi) are small-molecule therapies used in inflammatory bowel disease (IBD). We describe 8 patients with IBD who developed an eczematous eruption, presumed atopic dermatitis (AD), after stopping JAKi therapy. METHODS: This case series describes 8 patients with IBD who developed de novo AD after withdrawal of JAKi therapy. RESULTS: Median time to AD onset was 7 days (interquartile range 2–12). Two cases with biopsy-confirmed AD resolved after reinitiation of JAKi therapy and adjunct AD treatments. DISCUSSION: A subset of patients with IBD may have latent susceptibility to AD, unmasked by therapy cessation and potentially triggered by an immune rebound effect.

Year:

2025

Background: Studies on somatic mutations in cancer typically report single-nucleotide variants in coding regions, while mutations in short tandem repeats (STRs) are usually overlooked. Homopolymeric regions, a subset of STRs, are stretches of DNA where only a single nucleotide is repeated multiple times (e.g., AAAAA or TTTTT). Only recently have mutations in such STR regions been seen in colorectal cancer, where microsatellite instability (MSI) is common. In non-melanoma skin cancer (NMSC), MSI is rare. In this study, we focus on somatic mutations in such homopolymeric regions in NMSC and their functional implications. Methods: We performed targeted DNA sequencing (paired tissue and blood from the same individual), using more than 400 cancer-related genes from 32 NMSC patients as cases and non-lesional skin tissue from 16 independent individuals as controls. Results: We identified NMSC-associated STR somatic mutations. These are associated with the dysregulation of DNA damage and repair mechanisms. In artificial intelligence (AI) predictive modeling, these markers could successfully differentiate basal cell carcinoma (BCC) and non-lesional skin tissue. To our knowledge, we present the first study focusing on STR somatic mutations in multiple cancer-related genes in NMSC found only in tumor tissue and not in non-lesional skin tissue. Some of them (APC, BRAF) are associated with more pronounced dysregulation of relevant gene pathways (hedgehog, Notch signaling, and Wnt signaling). Conclusions: Our findings suggest that this STR somatic mutation status might potentially be used to select BCC patients who could benefit from certain precision therapy including hedgehog inhibitors, gamma-secretase inhibitors, anti-Vasuclar endothelial growth factor (VEGF), proteasome inhibitors, and immune check-point inhibitors.

Year:

2025

Arsenic (As) is a risk factor for non-melanoma skin cancer (NMSC). From a six-year follow-up study on 7000 adults exposed to As, we reported the associations of single-nucleotide variation in tumor tissue and gene expression. Here, we identify the associations of small deletions (DELs) and transcriptomic profiles in NMSC. Comparing the (a) NMSC tissue (n = 32) and corresponding blood samples from each patient, and (b) an independent set of non-lesional, healthy skin (n = 16) and paired blood, we identified NMSC-associated DELs. Differential expressions of certain gene pathways (TGF-β signaling pathway, IL-17 pathway, PD-L1 pathway, etc.) showed significant interactions with these somatic DELs and As exposure. In low-As-exposure cases, the DELs in APC were associated with the up-regulation of inflamed T-Cell-associated genes by a fold change (FC) of 8.9 (95% CI 4.5–17.6), compared to 5.7 (95% CI 2.9–10.8) without APC DELs; in high-As-exposure cases, the APC DELs were associated with an FC of 5.8 (95% CI 3.5–9.8) compared to 1.2 (95% CI −1.3 to 1.8) without APC DELs. We report, for the first time, the significant associations of somatic DELs (many in STR regions) in NMSC tissue and As exposure with many dysregulated gene pathways. These findings may help in selecting groups of patients for potential targeted therapy like PD-L1 inhibitors, IL-17 inhibitors, and TGF-β inhibitors in the future.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2021

Collaborators (11)

Farzana Jasmine

Staff Scientist

University of Chicago

UNITED STATES
View details

David Choi

University of Chicago Medicine

UNITED STATES
View details

Muhammad Kibriya

Research Associate Professor

University of Chicago

UNITED STATES
View details

Joann G. Elmore

Professor

University of California

UNITED STATES
View details

Derek Reiman

Research Assistant Professor

Toyota Technological Institute at Chicago

UNITED STATES
View details

Angad Chadha

Physician / Asst Prof

University of Chicago

UNITED STATES
View details

Peter M. Ferguson

Melanoma Institute Australia

AUSTRALIA
View details

Robert Grossman

University of Chicago

UNITED STATES
View details

Benjamin McDonald

-

UNITED STATES
View details

David Rubin

Professor

University of Chicago

UNITED STATES
View details

Richard A. Scolyer

Faculty Member

University of Sydney

AUSTRALIA
View details